TG Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3020 Carrington Mill Blvd Ste 475, Morri...Phone Number
(212) 554-4484Website
www.tgtherapeutics.comRevenue
$799.5 MillionStock Symbol
TGTXIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
2
2
2
2
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York.Explore more
TG Therapeutics Org Chart
SC
Senior Director (Analytics & Insights)
AH
Regional Director, Marketing (East)
BS
Director, Regional Marketing
MV
Director, Patient Marketing
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TG Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on TG Therapeutics recently announced quarterly report
Click to see if TG Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if TG Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at TG Therapeutics
Funding: Get notified immidiatlly once TG Therapeutics has new funding data
TG Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when TG Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TG Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at TG Therapeutics
Find more new buyers
Compare Similar Companies to TG Therapeutics
Compare insights from companies similar to TG Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TG Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TG Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TG Therapeutics.
TG Therapeutics financials insights
Gather financial insights about TG Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$140M
TG Therapeutics Tech Stack
A closer look at the technologies used by TG Therapeutics
Most Recent Scoops
Project
TG Therapeutics has reported positive Phase I bioavailability data for its proprietary subcutaneous formulation of BRIUMVI, with a fully enrolled Phase III study evaluating a quarterly dosing schedule currently underway and top-line results expected around year-end 2026 or early 2027. A successful subcutaneous BRIUMVI would allow TG Therapeutics to compete in the self-administered therapy segment, potentially more than doubling BRIUMVI's current addressable market.
Pharmaceuticals, Clinical Operations
Project
TG Therapeutics has reported positive top-line Phase III results from its ENHANCE study, demonstrating that BRIUMVI can be initiated with a single 600 milligram infusion, replacing the currently approved two-visit day one and day 15 initiation schedule. If approved, this simplified initiation schedule could be available as early as mid-2027.
Pharmaceuticals, Clinical Operations
Person-Based
Earnings, Finance
Earnings
TG Therapeutics has reported operating expenses of approximately $150 million for Q2 2026, including approximately $55 million in charges associated with subcutaneous and secondary source manufacturing activities, with underlying operating expenses of approximately $95 million excluding those charges. Full-year 2026 operating expense projections include approximately $100 million for manufacturing-related activities.
Earnings, Business Finance, Finance, Manufacturing Operations
Earnings
Earnings, Finance
TG Therapeutics News & Media
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago. Speaking at a Canaccord Genuity event, President, CEO and Co-Founder KTG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call August 3, 2026 8:30 AM EDTCompany ParticipantsJenna Bosco - Senior Vice President of Corporate...TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 millionTG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TG Therapeutics
Sign Up For FreeTo access detailed company insights
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York.... Read More
